Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05526079 · ClinicalTrials.gov registry record · Phase 2
Watchful Waiting for Complete Responders to Therapy in Rectal Cancer
A Phase 2 study of Rectal Cancer, sponsored by Henry Ford Health System.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05526079: Recruiting Phase 2 study of Rectal Cancer, sponsored by Henry Ford Health System.
NCT05526079 is a Phase 2 study of Rectal Cancer that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 30 participants, below the 3,166-participant average among 70 other Rectal Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05526079, a Phase 2 study of Rectal Cancer, is actively recruiting participants, sponsored by Henry Ford Health System.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this project is to determine if in a selected group of patients, at higher risk of wound dehiscence and other complications, treatment by local excision and management by a "watchful waiting" or an initial "non-operative management" approach, with an offer of radical resection only to those patients whose tumors demonstrate "regrowth" will maintain acceptable local control and overall survival rate for the whole cohort.
Primary Outcome
Survival without recurrence of the cancer
Conditions Studied
Interventions
- OTHER Watchfuf waiting
Study Locations (1)
Michigan
- Ascension St. John Hospital - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-07-10 |
| Est. Completion | 2029-07-09 |
| Phase | Phase 2 |
What NCT05526079 shows while recruiting
NCT05526079 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 3,166-participant average among 70 other Rectal Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Rectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Watchfuf waiting is the first listed.
NCT05526079 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05526079 about?
NCT05526079 is a clinical study titled "Watchful Waiting for Complete Responders to Therapy in Rectal Cancer". The purpose of this project is to determine if in a selected group of patients, at higher risk of wound dehiscence and other complications, treatment by local excision and management by a "watchful waiting" or an initial "non-operative management" approach, with an offer of radical resection only to...
What is the current status of trial NCT05526079?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2018-07-10. Estimated completion is 2029-07-09.
What conditions does trial NCT05526079 study?
This clinical trial studies the following conditions: Rectal Cancer.
What interventions are being tested in trial NCT05526079?
The interventions under investigation include: Watchfuf waiting (OTHER).
Who is sponsoring clinical trial NCT05526079?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05526079 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05526079's enrollment target sits among peer trials
30 52nd of 70 higher than 16 of 70 other Rectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
RECRUITING · Phase 2
-
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
RECRUITING · Phase 2
-
Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001
RECRUITING · Phase 2
-
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 2
-
Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer
RECRUITING · Phase 2
-
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy